Arthritis Education
RA Trial Measures in Clinical Practice: Is it time?
Jointly sponsored by the Johns Hopkins University School of Medicine, The Institute for Johns Hopkins Nursing, and the University of Tennessee College of Pharmacy.
Measures of the impact, on rheumatoid arthritis (RA), of various treatments have been under development since the late 1970s. The widest use to date of these so-called outcome measures has been in the clinical trial arena and in the reporting of the long-term impact of disease on patient groups. Many clinicians feel that these same research and classification measures should be adaptable to the office setting but are unsure of their feasibility and utility. This program will attempt to translate the use of outcome measures from the clinical trial arena to the clinic.
Program Format
An Internet-based, CME/CE/CPE-accredited professional education program. Estimated time to complete this educational activity: 1 hour.
Target Audience
Rheumatologists, Nurses, and Pharmacists. There are no prerequisites.
Learning Objectives
Following this program, the participant should be able to:
- Outline the various outcome measures that have been designed or adapted for use in the evaluation of RA
- Describe the measures that are felt to be most adaptable to the clinical practice setting
- Characterize the various measures in regard to their utility in the clinic and their ease of use
- Describe the long acting agents most effective in improving patient outcomes
- Incorporate some or all of the described outcome measures in their clinical practice
Disclaimer
The opinions and recommendations expressed by faculty and other experts, whose input is included in this program, are their own. This enduring material is produced for educational purposes only. Uses of the Johns Hopkins University School of Medicine and The Institute for Johns Hopkins Nursing names imply review of educational format design and approach. Please review the complete prescribing information of specific drugs or combinations of drugs, including indications, contraindications, warnings and adverse effects before administering pharmacologic therapy to patients.
Accreditation This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of The Johns Hopkins University School of Medicine, The Institute for Johns Hopkins Nursing, and the University of Tennessee College of Pharmacy.
Physicians: The Johns Hopkins University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians.
Nurses: The Institute for Johns Hopkins Nursing is accredited as a provider of continuing education in nursing by the American Nurses Credentialing Center Commission on Accreditation.
Credit Designation Physicians: The Johns Hopkins University School of Medicine designates this educational activity for a maximum of 1 category 1 credit(s) toward the AMA Physician's Recognition Award. Each physician should claim only those credits that he/she actually spent in the activity.
Nurses: The Institute for Johns Hopkins Nursing designates this activity for a maximum of 1.2 contact hours. Claim only those contact hours actually spent in the activity.
Pharmacists: This program is approved for one (1) hour credit (0.1 CEUs) and is co-sponsored by the University of Tennessee College of Pharmacy who is approved by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmaceutical education. Program #: 064-999-05-252-H01.
Grievance Policy
A participant, sponsor, faculty member or other individual wanting to file a grievance with respect to any aspect of a program sponsored or co-sponsored by the UTCOP may contact the Associate Dean for Continuing Education in writing. The grievance will be reviewed and a response will be returned within 45 days of receiving the written statement. If not satisfied, an appeal to the Dean of the College of Pharmacy can be made for a second level of review.
Date of Release and Expiration
Physicians and Nurses: This course was released on June 30, 2005 and will expire on June 30, 2006. Credit cannot be awarded after this date.
Pharmacists: Credit cannot be awarded after June 2008. Estimated time to complete this educational activity: 1 hour.
Responsibility Statement
The Johns Hopkins University School of Medicine, The Institute for Johns Hopkins Nursing, and The University of Tennessee College of Pharmacy take responsibility for the content, quality and scientific integrity of this CME/CE activity.
Privacy Statement
The Johns Hopkins University School of Medicine (JHUSOM) and The Institute for Johns Hopkins Nursing (IJHN) are committed to protect the privacy of our participants. We maintain our Internet site as an information resource and service for health professionals. The Johns Hopkins University School of Medicine and The Institute for Johns Hopkins Nursing will keep your personal information confidential when you participate in an Internet based program. Your information will never be given to anyone outside of the JHUSOM and IJHN continuing education programs. The Johns Hopkins University School of Medicine and The Institute for Johns Hopkins Nursing collect only the information necessary to provide you with the services that you request.
Clifton O. Bingham III, MD(program chair)
Assistant Professor of Medicine
Divisions of Rheumatology and Allergy
Johns Hopkins University
Dr. Bingham is an Assistant Professor of Medicine with a primary appointment in the Division of Rheumatology and a secondary appointment in the Division of Allergy and Clinical Immunology. He received his MD from Columbia University, where he also completed Internship and Residency training in Internal Medicine. He trained in Clinical Rheumatology, as well as in Allergy and Clinical Immunology at the Brigham and Women’s Hospital in Boston. Dr. Bingham completed additional Postdoctoral Fellowship training at Harvard Medical School and served as an Attending Rheumatologist and Allergist/Immunologist at Brigham and Women’s and at Massachusetts General Hospital. He was on faculty at NYU-Hospital for Joint Diseases from 1999 through 2004 where he founded and directed the Peter D. Seligman Center for Advanced Therapeutics, a dedicated Rheumatology Clinical and Translational Research Unit. He was recruited to join the faculty as a member of the Arthritis Center at Johns Hopkins in 2005.
Dr. Bingham received the Dorothy Goldstein Young Scholar Award from the New York Chapter of the Arthritis Foundation and is the recipient of an Arthritis Investigator Award from the national Arthritis Foundation. He has served as principal investigator for multiple Phase II and III clinical trials for rheumatoid arthritis, psoriatic arthritis, and osteoarthritis and was a site Principal Investigator for the multicentered NIH Glucosamine Arthritis Intervention Trial (GAIT). He has been involved in more than 30 Phase I–IV Clinical Trials and registries for patients with rheumatic diseases. Dr. Bingham has served on an Expert Panel for Clinical Research at the NIH-NIDCR, on an NIH-NIAMS Special Emphasis Panel Study Section, and has served as a reviewer for rheumatology journals including Arthritis and Rheumatism, Arthritis Research and Therapy, and Journal of Rheumatology. He has authored more than 18 articles and reviews on topics in Inflammation, Mast Cell Biology, Rheumatoid Arthritis, Psoriatic Arthritis, and Osteoarthritis, six book chapters, including one in the Primer on Rheumatic Diseases, several topics in UpToDate in Medicine , and more than 28 Abstracts presented at national and international scientific meetings. He has worked with several pharmaceutical companies in clinical trial design and data analysis for OA and RA investigational therapeutic agents. He is active in the American College of Rheumatology, serving on the Professional Meeting Planning Committee; Chairman of the 2006 Spring Rheumatology State-of-the-Art Meeting; the Innovative Therapies in Autoimmune Diseases Planning Committee; RA Clinical Therapeutics Abstract Selection Committee; and Chairman of the RA Study Group. He has worked with the Group for Research in Psoriasis and Psoriatic Arthritis (GRAPPA) and has participated in biennial OMERACT meetings, chairing a Special Interest Group to evaluate the comprehensive evaluation of single joints in clinical trials of emerging therapeutics including gene therapy. He currently serves as the Director of the Johns Hopkins Arthritis Website.
His interests are in novel therapeutic agents for the treatment of inflammatory arthritis and osteoarthritis, as well as in chronic autoimmune urticaria. He is actively involved in studies to determine risk factors for imminent progression in osteoarthritis. He is directing another project in collaboration with dental investigators to understand shared disease mechanisms in rheumatoid arthritis and periodontal disease.
Joel M. Kremer, MD
Director of Research
Center for Rheumatology, Albany, NY
Joel M. Kremer, MD, is a graduate of Temple University School of Medicine. He completed both a residency in internal medicine and fellowship in rheumatology at the Albany Medical Center Hospital and the Albany Medical College.
Dr. Kremer serves on the faculty of the Albany Medical College; was appointed professor of medicine in 1990 and became the head of the division of rheumatology in 1992. Dr. Kremer has been active in the American College Rheumatology, serving as the president of the Northeast Region in 1992. He serves on the ACR committee for the publication of Arthritis and Rheumatism and is on the board of directors of the Northeast New York Chapter of the Arthritis Foundation.
Dr. Kremer has contributed over 85 original articles to the scientific literature. In addition, he has authored 14 book chapters and edited 3 texts on the rheumatic diseases. In addition to his practice activities he serves as the director of research of the Center for Rheumatology in Albany and is a founder and the current president of the Consortium of Rheumatology Researchers of North America (CORRONA), a national organization for furthering research in patients with rheumatic diseases.
Alan K. Matsumoto, MD
Johns Hopkins University School of Medicine
Alan K. Matsumoto, MD, is a rheumatologist in private practice with Arthritis and Rheumatism Associates in the Washington, DC area. He is also on part-time faculty at the Johns Hopkins University School of Medicine as an assistant professor of medicine in the division of rheumatology.
Dr. Matsumoto earned his BS in chemistry at Stanford University, and his MD at the University of Illinois at Chicago. He served his internship and residency in internal medicine at the University of Medicine and Dentistry of New Jersey’s Robert Wood Johnson Medical School. He served as chief resident at the Medical Center at Princeton and then went on to a fellowship in rheumatology at Johns Hopkins University.
Dr. Matsumoto is a frequent invited lecturer, and has published numerous peer-reviewed articles and chapters. He is a member of the American College of Physicians, the American College of Rheumatology and recently served as president of the Rheumatism Society of the District of Columbia.
Full Disclosure Policy Affecting CME/CE Activities
As providers accredited by the Accreditation Council for Continuing Medical Education (ACCME) and American Nursing Credentialing Center, it is the policy of the Johns Hopkins University School of Medicine and the Institute for Johns Hopkins Nursing to require the disclosure of the existence of any significant financial interest or any other relationship a faculty member or a provider has with the manufacturer(s) of any commercial product(s) discussed in an education presentation. This is also the policy of the University of Tennessee College of Pharmacy. The presenting faculty reported the following:
Dr. Clifton O. Bingham III has received grants and research support from Abbott, Alexion, Amgen, Arthritis Foundation, Bristol Myers Squibb, Centacor, Genentech, Merck, NIH, and Regeneron. He has served as a consultant for Abbott, Amgen, Aventis, Merck, McNeil, Novartis, Regeneron, and Procter and Gamble.
Dr. Alan K. Matsumoto has no relationships to disclose.
Dr. Joel M. Kremer has received honorarium, grants and research support from, and has been a consultant for, Amgen, Abbott, Aventis, BMS, Centocor, and Genentech.
He is founder and director of CORRONA.
No faculty member has indicated that their presentation will include information on off-label products.
This educational program is supported through an educational grant from Abbott Laboratories.
© 2005 The Johns Hopkins University School of Medicine, The Institute for Johns Hopkins Nursing and The University of Tennessee College of Pharmacy. All rights reserved.
